The global Influenzavirus B Infection Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Influenzavirus B Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Influenzavirus B Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
The Asia Pacific market for Influenzavirus B Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Influenzavirus B Infection Drug include Sanofi, AbbVie Inc, Vectura Group Plc, Vaxart Inc, TSRL Inc, SK Chemicals Co Ltd, Shionogi & Co Ltd, Sanofi Pasteur SA and Romark Laboratories LC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Influenzavirus B Infection Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Influenzavirus B Infection Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Influenzavirus B Infection Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Influenzavirus B Infection Drug.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Influenzavirus B Infection Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Influenzavirus B Infection Drug Market by Company
- Sanofi
- AbbVie Inc
- Vectura Group Plc
- Vaxart Inc
- TSRL Inc
- SK Chemicals Co Ltd
- Shionogi & Co Ltd
- Sanofi Pasteur SA
- Romark Laboratories LC
- Park Active Molecules
- Novavax Inc
- Mucosis BV
- MedImmune LLC
- Medicago Inc
- Kineta Inc
- Inovio Pharmaceuticals Inc
- Green Cross Corp
- GlaxoSmithKline Plc
- Fujifilm Holdings Corporation
- Daiichi Sankyo Company Ltd
- ContraFect Corp
- Cadila Healthcare Ltd
- BioCryst Pharmaceuticals Inc
- Aphios Corp
- Amarillo Biosciences Inc
- Altravax Inc
- Adimmune Corp
Influenzavirus B Infection Drug Segment by Type
- KIN-1400
- GC-3106A
- CF-403
- APP-309
- Others
Influenzavirus B Infection Drug Segment by Application
Influenzavirus B Infection Drug Segment by Region
- North America
- United States
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Southeast Asia
- South America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
- This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenzavirus B Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
- This report will help stakeholders to understand the global industry status and trends of Influenzavirus B Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
- This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
- This report stays updated with novel technology integration, features, and the latest developments in the market.
- This report helps stakeholders to gain insights into which regions to target globally.
- This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenzavirus B Infection Drug.
- This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Influenzavirus B Infection Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Influenzavirus B Infection Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
